Nanotechnology-driven drug delivery systems have emerged as a transformative approach in modern pharmaceutical research, offering innovative solutions to overcome the limitations of conventional drug delivery. These systems utilize nanoscale carriers such as liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, and nanostructured lipid carriers to enhance drug solubility, stability, bioavailability, and targeted delivery. By enabling precise control over drug release and distribution, nanocarriers significantly improve therapeutic efficacy while minimizing systemic toxicity and adverse effects. The integration of surface functionalization strategies allows for active targeting through ligand–receptor interactions, while passive targeting exploits physiological phenomena such as the enhanced permeability and retention (EPR) effect, particularly in tumor tissues. Recent advancements have also introduced stimuli-responsive nanocarriers that respond to environmental triggers such as pH, temperature, and enzymes, thereby enabling site-specific drug release. Nanotechnology has demonstrated substantial potential across diverse therapeutic areas including oncology, cardiovascular diseases, neurological disorders, and infectious diseases. Moreover, the role of nanocarriers in gene delivery and vaccine development has gained significant attention, particularly with the success of lipid nanoparticle-based mRNA vaccines. Despite these promising advancements, challenges related to toxicity, immunogenicity, large-scale manufacturing, regulatory approval, and long-term safety remain critical concerns. The translation of nanomedicines from laboratory research to clinical application requires robust analytical characterization, standardized protocols, and comprehensive regulatory frameworks. This review highlights the latest innovations in nanotechnology-based drug delivery systems, discusses their clinical translation, and addresses the challenges and future perspectives in this rapidly evolving field.